Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A First-In-Human Study of LY3839840 in Healthy Participants
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 178
- Registration Number
- NCT06153355
- Locations
- 🇺🇸
CenExel ACT, Anaheim, California, United States
🇺🇸Fortrea Clinical Research Unit, Madison, Wisconsin, United States
A Study of LY3971297 in Healthy Participants
- Conditions
- ObesityHypertensionHealthy
- Interventions
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 225
- Registration Number
- NCT06148272
- Locations
- 🇯🇵
Clinical Research Hospital Tokyo, Shinjuku-ku, Tokyo, Japan
🇺🇸CenExel ACT, Anaheim, California, United States
🇺🇸ICON Early Phase Services, San Antonio, Texas, United States
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Conditions
- ObesityOverweight
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1040
- Registration Number
- NCT06143956
- Locations
- 🇺🇸
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona, United States
🇺🇸HOPE Research Institute, Phoenix, Arizona, United States
🇺🇸Headlands Research - Scottsdale, Scottsdale, Arizona, United States
A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes MellitusHealthy
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 66
- Registration Number
- NCT06132126
- Locations
- 🇺🇸
Labcorp CRU, Dallas, Texas, United States
🇺🇸Qps-Mra, Llc, Miami, Florida, United States
🇺🇸CenExel ACT, Anaheim, California, United States
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
- Conditions
- ObesityOverweight and Obesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 179
- Registration Number
- NCT06124807
- Locations
- 🇺🇸
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona, United States
🇺🇸Headlands Research - Scottsdale, Scottsdale, Arizona, United States
🇺🇸The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson, Arizona, United States
A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis
- Conditions
- Atopic DermatitisHealthy
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT06119529
- Locations
- 🇺🇸
CenExel ACT, Anaheim, California, United States
🇺🇸Fortrea Clinical Research Unit, Daytona Beach, Florida, United States
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell LungNeoplasm Metastasis
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1016
- Registration Number
- NCT06119581
- Locations
- 🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Banner University Medical Center Phoenix, Phoenix, Arizona, United States
A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 35
- Registration Number
- NCT06111521
- Locations
- 🇺🇸
ICON Early Clinical & Bioanalytical Solutions, Salt Lake City, Utah, United States
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 520
- Registration Number
- NCT06109311
- Locations
- 🇺🇸
Consano Clinical Research, LLC, Shavano Park, Texas, United States
🇺🇸Texas Valley Clinical Research, Weslaco, Texas, United States
🇧🇷L2IP - Instituto de Pesquisas Clínicas, Brasília, Distrito Federal, Brazil
A Study of [14C]-LOXO-783 in Healthy Adult Participants
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT06102512
- Locations
- 🇺🇸
Fortrea Clinical Research, Madison, Wisconsin, United States